Mostrar el registro sencillo del ítem

dc.contributor.authorPeral, Jose
dc.contributor.authorEstella García, Angel 
dc.contributor.authorNuvials, Xavier
dc.contributor.authorRodríguez, Alejandro
dc.contributor.authorSeijas, Iratxe
dc.contributor.authorSoriano, Cruz
dc.contributor.authorSuberviola, Borja
dc.contributor.authorZaragoza, Rafael
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-04-30T06:44:06Z
dc.date.available2024-04-30T06:44:06Z
dc.date.issued2023
dc.identifier.issn2309-608X
dc.identifier.urihttp://hdl.handle.net/10498/32034
dc.description.abstractThe aim of this study was to establish practical recommendations for the diagnosis and treatment of influenza-associated invasive aspergillosis (IAPA) based on the available evidence and experience acquired in the management of patients with COVID-19-associated pulmonary aspergillosis (CAPA). The CAPA/IAPA expert group defined 14 areas in which recommendations would be made. To search for evidence, the PICO strategy was used for both CAPA and IAPA in PubMed, using MeSH terms in combination with free text. Based on the results, each expert developed recommendations for two to three areas that they presented to the rest of the group in various meetings in order to reach consensus. As results, the practical recommendations for the management of CAPA/IAPA patients have been grouped into 12 sections. These recommendations are presented for both entities in the following situations: when to suspect fungal infection; what diagnostic methods are useful to diagnose these two entities; what treatment is recommended; what to do in case of resistance; drug interactions or determination of antifungal levels; how to monitor treatment effectiveness; what action to take in the event of treatment failure; the implications of concomitant corticosteroid administration; indications for the combined use of antifungals; when to withdraw treatment; what to do in case of positive cultures for Aspergillus spp. in a patient with severe viral pneumonia or Aspergillus colonization; and how to position antifungal prophylaxis in these patients. Available evidence to support the practical management of CAPA/IAPA patients is very scarce. Accumulated experience acquired in the management of CAPA patients can be very useful for the management of IAPA patients. The expert group presents eminently practical recommendations for the management of CAPA/IAPA patients.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceJournal of Fungi - 2023, Vol. 9 n. 3 pp. 1-19es_ES
dc.subjectinfluenza-associated invasive aspergillosises_ES
dc.subjectCOVID-associated invasive aspergillosises_ES
dc.subjectCOVID-19es_ES
dc.subjectintensive care unites_ES
dc.subjectcritical patientses_ES
dc.titleManaging the Next Wave of Influenza and/or SARS-CoV-2 in the ICU—Practical Recommendations from an Expert Group for CAPA/IAPA Patientses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/JOF9030312
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution 4.0 Internacional